KNSA

Kiniksa Pharmaceuticals, Ltd. (KNSA) ESG Analysis Analysis (2026)

Invetso Score: 6.9/10 — Balanced · Last Updated: 2026-08-01

Environmental

KNSA’s R&D intensity of 15.1% of revenue indicates a science-led operating model, but peers in specialty pharma often show similarly elevated research footprints.

The company’s low debt-to-equity ratio of 0.01 reduces capital pressure that can otherwise constrain environmental investments, though this is broadly consistent with peer biotech balance sheets.

Negative net debt to EBITDA suggests excess liquidity, which can support compliance and facility standards, yet it does not distinguish KNSA materially from cash-rich peers.

No disclosed environmental metrics on emissions, energy, or waste limit evidence of superior environmental management versus peers, keeping the score in the moderate range.

Social

KNSA’s 4.3% stock-based compensation to revenue suggests moderate reliance on equity incentives, which can support talent retention but is not clearly better than peers.

The company’s R&D-heavy model depends on specialized scientific labor, creating human-capital concentration risk that is common across biotech peers.

No disclosed workforce, safety, diversity, or patient-access metrics in the provided data prevent a stronger relative assessment of social performance.

The absence of major controversy data avoids a penalty, but peer-relative social positioning remains only moderate because evidence of differentiated practices is limited.

Governance

KNSA’s very low debt-to-equity ratio indicates conservative leverage, which reduces creditor oversight pressure and supports governance flexibility versus more levered peers.

Negative net debt to EBITDA implies a net cash position, which lowers refinancing risk and generally strengthens board control over capital allocation.

Stock-based compensation at 4.3% of revenue appears contained, suggesting less dilution pressure than many growth-stage biotech peers with heavier equity issuance.

The lack of filing-based detail on board independence, audit quality, and shareholder rights limits a higher score, but the capital structure remains a relative governance strength.

Overall Score

KNSA’s ESG profile is moderate overall because conservative leverage and contained equity compensation support governance, while limited disclosed environmental and social metrics cap differentiation versus peers.

Score Driver: Conservative Capital Structure Is The Clearest Relative ESG Strength, But Limited Disclosure Prevents A Higher Peer-Relative Score.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Kiniksa Pharmaceuticals, Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →